Exchange: NASDAQ·Updated 07:46 PM EDT

UTHR News

News
all
press releases
United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the companys Board of Directors has authorized a new share repurchase program for up to $2 billion of the companys common stock, available through October 21, 2027. We have the balance sheet and free...
Business Wire
United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the companys Board of Directors has authorized a new share repurchase program for up to $2 billion of the companys common stock, available through October 21, 2027. We have the balance sheet and free...
Business Wire
More News
United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2026 financial results in a press release that will be issued on Wednesday, November 4, 2026, at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast on Wednesday...
Business Wire
United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the opening of its third Designated Pathogen-Free (DPF) facility, The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility, in Houston, Texas. United Therapeutics opened its...
Business Wire
United Therapeutics Announces FDA Clearance to Proceed with SUMMIT Clinical Trial for Treprostinil SMI in PH-COPD
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance under the companys investigational new drug application to proceed with the SUMMIT clinical trial of treprostinil SMI in PH-COPD. The...
Business Wire
Stocktwits Wall Street Wrap: Crocs, Liquidia Win Upgrades While SpaceX Competition And Grocery Woes Put AST SpaceMobile, Albertsons Under Pressure
Growth prospects, business challenges, legal changes, and rising competition from SpaceX shaped Wall Street activity this week.
Stocktwits
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label
Liquidia settles six legal disputes with United Therapeutics, securing Yutrepia access for PAH patients but facing $380.7 million in payments and a narrower drug label.
Zacks
SGIOY or UTHR: Which Is the Better Value Stock Right Now?
SGIOY vs. UTHR: Which Stock Is the Better Value Option?
Zacks
LQDA Stock Rockets 40% Today – BTIG Calls United Therapeutics Settlement ‘Better Than Best-Case Scenario’
LifeSci Capital said the agreement removes a major obstacle that could have discouraged potential buyers from pursuing an acquisition of Liquidia.
Stocktwits
Liquidia Corporation Stock Is Trending In After-Hours Following United Therapeutics Settlement: What You Should Know
Liquidia shares surged 42.48% in after-hours trading after settling all pending litigation with United Therapeutics over YUTREPIA patents.read more...
Benzinga
LQDA Explodes After Hours On Deal Ending Years Of Patent Fight, Keeping YUTREPIA On Market
The agreement resolves all six ongoing lawsuits between Liquidia, United Therapeutics and related parties.
Stocktwits

Advertisement|Remove ads.